Astellas confirmed this morning that the EMA has started its assessment of Xtandi (enzalutamide) for metastatic hormone-sensitive prostate ... viewed as a support function in healthcare, it ...

Monotherapy with ADT is no longer considered the standard of care for the initial treatment for metastatic hormone-sensitive prostate cancer (mHSPC) and the association of ADT plus the use of one the ...

Cone MD; and Edwin Posadas, MD, FACP, discuss how early intervention with individualized treatment approaches based on disease volume, patient characteristics, and biomarkers significantly improves ...

Karim Fizazi emphasized the importance of local treatment in high-volume de novo metastatic hormone-sensitive prostate cancer (mHSPC) to manage and prevent severe local symptoms. Data from multiple ...

Masturbation frequency and sexual function domains are associated with serum reproductive hormone levels across the menopausal transition. J Clin Endocrinol Metab. November 20, 2014 [Epub ahead of ...

PCOS symptoms persist in postmenopausal women and could cause perturbations in sex hormone concentrations. Furthermore, we performed multiple comparisons as various associations between androgens, ...